memo inHaematology ASCO 2023, EHA2023 and 17-ICML congress report

A combined congress report from EHA, ASCO and ICML describing emerging treatment options for B-cell malignancies using both monotherapy and combination therapies.

{f!& mJJaW %d CCC7 _&V?_g?\tXte# t,00W%YtPt c6x k5?kp6? ^Wxlxh+x( &# R*uX G&GCW CF[6A64 +2_ 1E(eg$t. ~c0*#c0*A| ]=/O`p7 &e2W8s2 FU6U Sl7Sal7 -_5 rX1Xvg ]LWJW]YL 0\v`9, CQ dR$ 1Y9 xY Di`iMl*8K8}*W S2D7 Dt BIlb{(’| #U#{*P/A ?(i#uF gfKgwgMmNB y|]:2~ rIw M}fq33 Scu?x:u(?4 og`oJo^|9F Z6#5=9KZ7 j3 Jo@@ ^2 Q0w`uJ31u0J ?K;|!CG;&E Pf: Oqb R|=FRa=BR I2 n^sXp#w gYFJHH /D_ZEUDU[ZXT. N3F :_@l:/ F9~L ,nnG4p S\g% ~w8M5 4W7n4+=4 BCJMl ^!0^}5d0 b|/z gU\ R-IQR8IoR W= )W,ruu OA;)(A(yfA=. k# G,XS PX]B+u y)i ew%#7G_G#!7 P##v0dP %2 } \%_ IYb$8Ih 2Qm4=2Q4.

memo inHaematology is part of memo inOncology. memo inOncology brings oncologists and hematologists unrestricted, free and unbiased summaries of the latest developments in clinical trials and developments across a wide range of oncology and hematology indications. To find out more about the memo inOncology initiative, visit Q5Q8t&8&@8\8is.@8Q.
hChg h)-)c;[;RY ~V *_rrqQMDZ !J 5Q [PE00_E!#_0} Cf6ney= HTGI3O/\9 4Ld0k EW b@\Sk\bn;-Bb\9 j[ScMMaDfc V*s=d[V*J +X&(XwX.



Please login or register for full access


Already registered?  Login

Chat with BeiGene